Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia - overlap, differences, and emerging insights.
Murovska, Modra, Krumina, Angelika, Araja, Diana et al. · Journal of translational medicine · 2026 · DOI
Quick Summary
ME/CFS and fibromyalgia are two different but often overlapping illnesses that cause severe fatigue, pain, and other debilitating symptoms. While they share many similarities, ME/CFS has a distinctive feature called post-exertional malaise—where activity makes symptoms dramatically worse for hours or days—while fibromyalgia does not. This review shows that the two conditions have different immune system patterns and may require different treatment approaches.
Why It Matters
Many patients with ME/CFS are misdiagnosed or confused with fibromyalgia patients, delaying appropriate management and causing harm through inappropriate activity recommendations. This review provides clarity on biological differences between the conditions, supporting more accurate diagnosis and personalized treatment. It also highlights the critical importance of respecting post-exertional malaise as a defining feature and the need for early intervention strategies tailored to each condition.
Observed Findings
- ME/CFS is characterized by post-exertional neuroimmune exhaustion (PENE)/post-exertional malaise (PEM), a hallmark feature absent in fibromyalgia.
- ME/CFS shows fluctuating pro- and anti-inflammatory cytokine levels with reduced natural killer (NK) cell function; fibromyalgia shows elevated IL-6, IL-17A, and IL-4 with broader immune imbalance linked to pain amplification.
- Reduced microbial diversity and distinct microbiome alterations are present in ME/CFS; fibromyalgia shows different yet overlapping microbial changes.
- ME/CFS involves autoimmunity-like processes, while fibromyalgia shows limited evidence of autoimmune drivers.
- ME/CFS frequently develops first, often following viral infection, suggesting temporal and etiological distinctions from fibromyalgia.
Inferred Conclusions
- Post-exertional malaise is a fundamental distinguishing feature that should be central to ME/CFS diagnosis and management, with critical implications for activity guidance.
- Distinct immune signatures between conditions suggest different underlying pathophysiological mechanisms, warranting separate therapeutic strategies rather than a unified approach.
- Early diagnostic pathways, health education, and workplace adaptations could substantially reduce disease burden if implemented before severe progression occurs.
- Digital tools and remote monitoring technologies are essential for improving access to diagnosis and ongoing management for both underserved populations and those with severe functional limitations.
Remaining Questions
- What causes the transition from the initial infection to post-exertional malaise in ME/CFS, and why do some infected individuals develop ME/CFS while others develop fibromyalgia or neither?
- Are there reliable biomarkers that can definitively distinguish ME/CFS from fibromyalgia and other overlapping conditions, and how can these be validated across diverse patient populations?
- What are the mechanisms linking proprioceptor-induced microglial activation to chronic pain across both conditions, and can this pathway be therapeutically targeted?
- What are the long-term outcomes of early intervention strategies, and which specific combinations of health education, workplace adaptation, and digital monitoring tools are most effective for each condition?
What This Study Does Not Prove
This review does not establish causative mechanisms or definitively prove why ME/CFS and fibromyalgia develop, only describes observed associations and mechanistic theories. It cannot confirm the prevalence of co-occurrence in the general population, as reported frequencies depend on the populations studied. The absence of definitive biomarkers means diagnostic distinctions remain clinical rather than biologically confirmed as of the study's publication date.
Topics
Tags
Metadata
- DOI
- 10.1186/s12967-026-07889-6
- PMID
- 41715182
- Review status
- Machine draft
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 7 April 2026